LibraGen

LibraGen uses innovative and proprietary functional genomic technologies in combination with industrial expertises to develop new bioprocesses for the discovery of novel bioactives and the improvement of production processes of added value molecules. Libragen's competitive edge is embodied by its ability to turn the huge genetic and chemical diversity of the 99% of bacteria that can not be cultured under conventional conditions into an accessible reservoir of biomolecules. These biomolecules are an unlimited bioresource for the development of active pharmaceuticals, agrochemicals and food ingredients as well as intermediates and bulk chemicals. Mastering the whole process from the discovery to the industrialisation, LibraGen reinforces its client's competitiveness and market share.

LibraGen aims at becoming a leader in the discovery and development of bacterial diversity-deriver processes for the industrial production of molecules that concerns the red (healthcare) as well as the white (industry) sectors of modern biotechnology. LibraGen masters the whole process, from lab-based discovery to industrialization. To maximise the industrial application of the research and development activity, LibraGen includes the industrial constraints of the used of bioprocesses for large scale production at early stage in the definition of the research strategy. The company intends to rapidly meet the needs of businesses due to increasing pressure on production costs and therefore the needs for innovation. LibraGen considers that this is a major business opportunity one which is likely to generate significant added value.